Biosequence Panel will Present the Only Non - Invasive Genomic Sequencing of Tumor in Spain: Guardant360TM
Monday, April 04, 2016
BioSequence, the only center in Spain advanced genomic analysis performed for all types of cancer, GUARDANT360TM present in the next edition of the National Symposium on Applied Genomics Oncology to be held on 26 April at the National Research Center Oncológicas- CNIO-.
The official presentation of the study run by Dr. Jesus Garcia Foncillas, scientific coordinator International Scientific and Medical Committee BioSequence, in order to provide a pioneering technology in the sector and completely new in Spain all medical group linked to oncology. In this regard and in accordance with Adriana Terradez, biotechnologist and director of BioSequence " We are convinced that it would be a great achievement GUARDANT360TM implant in Spanish daily clinical practice to optimize patient treatment. The study analyzes 70 genes with a simple blood sample and prevents further biopsies. "
GUARDANT360TM It is the only non-invasive tumor in Spain genomic sequencing panel that uses a new technology able to isolate the circulating tumor DNA in blood to identify genomic alterations present in the tumor that have diagnostic value, prognostic and therapeutic.
Tumors cancer patients release a percentage of the blood cells can be isolated and analyzed by sequencing a genomic study allowing to perform without the need to subject the patient to an intervention to obtain a solid tumor biopsy directly.
Until not long ago, to conduct a genomic study it was necessary to perform a biopsy solid. Now with the advent of liquid biopsy and specifically with the study GUARDANT360TM BioSequence with Labco Diagnostics Quality distributed exclusively in Spain, characterize tumors is faster and easier. His practice provides various advantages such as avoiding making new biopsies in cases that pose a risk to the patient or is not possible to perform the procedure; It provides relevant individual information related to tumor development; allows direct association between the detected abnormalities and treatment options; detected early progress of the patient and / or treatment failures rather than conventional imaging techniques; It allows monitoring the patient before and after surgery and facilitates obtaining global information tumor or tumors as well as intratumoral heterogeneity.
"The liquid biopsy is a tool to get closer to oncology precision. In BioSequence we committed to this innovative technique because we believe fully in their usefulness and specifically committed to GUARDANT360TM laboratory Guardant Health with whom we work closely. There are many studies of liquid biopsy in the market indicated for genes specifically us with GUARDANT360TM do ultrasequencing that is, we analyze many genes in a single test getting much more critical information , "explains Adriana Terradez, biotechnologist and director of BioSequence.
About BioSequence
BioSequence is the only center in Spain advanced genomic analysis performed for all types of cancer, the first company to introduce the latest advances in oncology Precision the Spanish clinical practice.
BioSequence collaborates with international reference laboratories as OncoDNA, Guardant Health in California, Baylor Miraca Cancer Genetics Laboratory in Houston, Texas Children's Hospital, N of One, ... they are to provide the most advanced molecular diagnostic technologies that allow oncologists offer treatments tailored the characteristics of their patients and improve their results and offering the highest quality and scientific rigor.
Located in the Technological Park of Valencia, it operates throughou